ABVC BioPharma Past Earnings Performance
Past criteria checks 0/6
ABVC BioPharma's earnings have been declining at an average annual rate of -23%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 10.5% per year.
Key information
-23.0%
Earnings growth rate
-3.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 10.5% |
Return on equity | -134.2% |
Net Margin | -6,898.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt
Mar 13Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute
Oct 05ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug
Sep 23ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?
Aug 18ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M
Aug 17ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial
Jul 13Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute
Jun 30Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?
Apr 04Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Dec 09Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Aug 05Revenue & Expenses BreakdownBeta
How ABVC BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -11 | 7 | 1 |
30 Sep 23 | 1 | -12 | 7 | 2 |
30 Jun 23 | 1 | -13 | 9 | 3 |
31 Mar 23 | 1 | -12 | 9 | 3 |
31 Dec 22 | 1 | -16 | 13 | 3 |
30 Sep 22 | 0 | -19 | 17 | 1 |
30 Jun 22 | 0 | -18 | 16 | 1 |
31 Mar 22 | 0 | -18 | 16 | 1 |
31 Dec 21 | 0 | -13 | 11 | 1 |
30 Sep 21 | 0 | -10 | 10 | 1 |
30 Jun 21 | 0 | -10 | 9 | 1 |
31 Mar 21 | 1 | -10 | 9 | 1 |
31 Dec 20 | 0 | -10 | 8 | 1 |
30 Sep 20 | 1 | -6 | 5 | 1 |
30 Jun 20 | 1 | -5 | 4 | 1 |
31 Mar 20 | 1 | -4 | 4 | 1 |
31 Dec 19 | 1 | -4 | 3 | 1 |
30 Sep 19 | 1 | -6 | 3 | 1 |
30 Jun 19 | 0 | -6 | 2 | 1 |
31 Mar 19 | 0 | -6 | 2 | 1 |
31 Dec 18 | 0 | -6 | 2 | 1 |
30 Sep 18 | 0 | -2 | 1 | 0 |
30 Jun 18 | 0 | -5 | 1 | 3 |
31 Mar 18 | 0 | -5 | 1 | 3 |
31 Dec 17 | 0 | -4 | 1 | 3 |
30 Sep 17 | 0 | -4 | 1 | 3 |
30 Jun 17 | 0 | -1 | 1 | 0 |
31 Mar 17 | 0 | -1 | 1 | 0 |
31 Dec 16 | 0 | -8 | 1 | 7 |
30 Sep 16 | 0 | -11 | 1 | 10 |
31 Dec 15 | 0 | -5 | 2 | 4 |
Quality Earnings: ABVC is currently unprofitable.
Growing Profit Margin: ABVC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABVC is unprofitable, and losses have increased over the past 5 years at a rate of 23% per year.
Accelerating Growth: Unable to compare ABVC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABVC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.9%).
Return on Equity
High ROE: ABVC has a negative Return on Equity (-134.18%), as it is currently unprofitable.